How to Buy Pliant Therapeutics Stock
Pliant Therapeutics Inc
Pliant Therapeutics, Inc. , a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.
Pliant Therapeutics stock last closed at $12.66, up 7.11% from the previous day, and has decreased 43.25% in one year. It has underperformed other stocks in the Biotechnology industry by 0.22 percentage points. Pliant Therapeutics stock is currently +12.93% from its 52-week low of $11.21, and -48.83% from its 52-week high of $24.74.
There are currently 60.24M PLRX shares outstanding. The market capitalization of PLRX is $762.63M. In the past 24 hours, 690,964 PLRX shares were traded.
How to Buy Pliant Therapeutics Stock
Wondering how to invest in Pliant Therapeutics stock? Here's how.
- Decide where to buy Pliant Therapeutics stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you figure out where to buy Pliant Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Put funds into your investment account: Select your payment method and add your information.
- Evaluate Pliant Therapeutics stock: The Pliant Therapeutics ticker symbol is PLRX. Is Pliant Therapeutics stock a good investment? Should you buy shares of PLRX? How do PLRX's underlying business fundamentals look? Do top analysts think Pliant Therapeutics is a good buy? Why has PLRX's stock price moved recently? (Hint: Our stock market analysis website can help you understand if PLRX is a good stock to buy).
- Execute your PLRX buy order: Decide if you will purchase PLRX shares at the current market price or use a limit order to purchase PLRX shares at a given price.
- Get the latest scoop on your investment in PLRX: Create a watchlist to important updates regarding your new investment in Pliant Therapeutics shares.
Step 1: Decide where to buy Pliant Therapeutics stock
You will need a brokerage account in order to access the NASDAQ market and buy PLRX shares.
Our favorite brokerage: eToro
Based on our research, eToro is the best place to buy stocks. Here's why:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Tech to Real Estate, New York to London — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro today.
Open eToro AccountStep 2: Open your brokerage account
Now that you've selected the right brokerage, you need to fill out some personal details so you are able to buy PLRX stock today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to start your new trading account.
- Submit your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you have created your account on the best app for stock investing, you can securely and quickly fund your account:
Check out the video below to see the process of transferring funds into your new investment account.
Step 4: Evaluate Pliant Therapeutics stock
After you have decided on the best place to buy Pliant Therapeutics stock, it's absolutely critical to research their stock before you invest, so you can wrap your head around the risk and opportunity.
Overview of key PLRX info
Fundamentals of PLRX
WallStreetZen was designed to help part-time investors perform more in-depth fundamental analysis.
You can see all of the due diligence checks on PLRX's stock page.
Is PLRX stock undervalued?
Investors use many financial metrics, analyses, models, and charts to gauge PLRX's intrinsic value.
Using relative valuations methods:
- PLRX may be undervalued based on its P/B ratio of 1.61x, relative to Biotechnology industry P/B ratio of 6.02x
You can do more valuation research on PLRX's stock here.
PLRX Financial Health
Signs that PLRX is financially healthy:
- Total PLRX debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the PLRX balance sheet.
- PLRX has $495.73M in cash and short term investments. This is sufficient to cover its annual cash burn of $117.28M.
- PLRX has a low debt to equity ratio of 0.08.
- PLRX has cash burn of 117282000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the PLRX balance sheet.
Signs that PLRX is not financially healthy:
- PLRX profit margin has gone down from -1,273.3% to -10,211.1% in the past year.
Do analysts think it's a good time to buy PLRX stock
Out of 3 Wall Street analysts who give forecasts on PLRX, the consensus analyst rating on Pliant Therapeutics is a Buy
Please note that analyst ratings are not recommendations, nor are they financial advice.
You can dig deeper into what analysts are projecting on the Pliant Therapeutics stock forecast page.
Metrics for Advanced PLRX Traders
PLRX Performance Metrics
Last year, PLRX revenue was $1.58M. Over the past 4 year, PLRX's revenue has increased by -59.21% per year. This was slower than the Biotechnology industry average of 28.49%.
Dive into PLRX's earnings and revenue performance here.
Latest Insiders Trades at PLRX
In the past 12 months, executives and large shareholders at PLRX have sold more shares than they have bought.
Bernard Coulie, President and CEO of PLRX, was the latest PLRX insider to sell. They sold $443,172.83 worth of PLRX stock on Jan 17, 2024.
Dig into more about who owns PLRX shares here.
Does PLRX stock generate passive income?
No, Pliant Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about PLRX
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your PLRX buy order
You have two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are usually fine. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at an exact dollar amount, place a limit order.
Hit the Open button and eToro will execute your order.
If you require additional help with buying stocks on eToro, watch the how to video below:
Step 6: Get the latest scoop on your investment in PLRX
Now that you own some PLRX stock, you'll want to stay up-to-date on your new investment.
Add PLRX to a watchlist to monitor your PLRX stock.
PLRX Feed
How to Buy Stock in Pliant Therapeutics
To reiterate, here are the 6 steps you need to take to buy Pliant Therapeutics stock right now:
- Decide where to buy Pliant Therapeutics stock
- Open your brokerage account
- Put funds into your investment account
- Evaluate Pliant Therapeutics stock
- Execute your PLRX buy order
- Get the latest scoop on your investment in PLRX
If you require a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to monitor your investment in Pliant Therapeutics, click the button below.
More Content You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.